← Back to Search

Outreach Methods for Cancer Trial Enrollment

N/A

Recruiting

Led By Walter Stadler

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

for prostate cancer patients: 2 or more increasing prostate specific antigen (PSA) values i the 6 months prior to visit

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to test different ways of reaching out to underrepresented minorities, specifically African Americans, and see how it affects their enrollment in early phase cancer treatment trials. Both patients and healthcare providers will be

Who is the study for?

This trial is for African American adults who are scheduled for new or follow-up oncology appointments at the study site. It includes those with a recent biopsy or imaging, prostate cancer patients with rising PSA levels, and others identified by researchers as likely needing treatment changes.

What is being tested?

The study is testing whether digital interventions and community outreach can increase enrollment of underrepresented minorities in early phase cancer clinical trials. Participants will either receive these novel outreach methods or no intervention.

What are the potential side effects?

Since this trial focuses on outreach methods rather than medical treatments, there are no direct physical side effects expected from participating in the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My PSA levels have been rising over the last 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Arm 3 (Digital Intervention + Community Outreach)Experimental Treatment2 Interventions

Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources. They will also be invited to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial. Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys.

Group II: Arm 2 (Digital Intervention)Experimental Treatment1 Intervention

Patient participants in this arm will receive digital messages (email, text, etc.) which include general educational information about clinical trials and available resources. Provider participants will also receive digital messages with educational materials and will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys.

Group III: Arm 1 (No Intervention)Active Control1 Intervention

Patient participants in this arm will receive no intervention but will be approached by their providers for participation in treatment clinical trials as per the usual methods. Provider participants will receive information on available clinical trials for which their patient participant may be eligible from study staff per usual methods. Provider participants will be asked to complete surveys.

0 / 1Eligibility criteria met